David Ricks, the chair and chief executive of Eli Lilly, speaking at The New York Times’s DealBook Summit, said his $750 ...

Eli Lilly & Co. Inc.’s stock LLY rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...

Analysts see the market for GLP-1 weight loss treatments rising to around $70 billion over the next five years.

We recently compiled a list of the Billionaire Ken Fisher’s Top 15 Stock Picks Heading Into 2025. In this article, we are ...

Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

The bears might point out that Eli Lilly's shares still look too expensive: The company's trailing price-to-earnings (P/E) ...

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...